Der er set større forbedringer med abatacept end med placebo i andre målinger af sygdomsaktivitet af reumatoid arthritis, som ikke er inkluderede i ACR- responskriterierne fx morgenstivhed.
10 Greater improvements were seen with abatacept than with placebo in other measures of rheumatoid arthritis disease activity not included in the ACR response criteria, such as morning stiffness.